Go To Global Site
Welcome to UCB in the United States

Our Response to the COVID-19 Pandemic

 

Patients are at the heart of everything we do, and UCB is committed to helping those impacted by the novel coronavirus, COVID-19. This includes helping patients maintain access to and answering any questions about UCB medicines, as well as putting patient and community care first in all our actions during these uncertain times.

The evolving COVID-19 pandemic has placed tremendous strain on medical healthcare systems worldwide as they focus on the ongoing extraordinary medical emergency. Taking this into consideration, UCB has taken measures to protect the patients we serve and others around the world. For information on our response, please check out the Frequently Asked Questions below.

Clinical Studies Information

In March 2020, the evolving COVID-19 pandemic led UCB to halt recruitment into ongoing clinical studies and delay all new study starts. This decision was taken in the interest of public health safety and to help reduce the strain on healthcare systems across the world during a time of extraordinary medical emergency. As of mid-May 2020, UCB began to restart clinical study recruitment, including new study starts, at clinical trials sites that meet our restart criteria.

UCB continues to proactively monitor the COVID-19 situation and will take any necessary precautionary steps in the interest of public health. Healthcare professionals and patients with questions related to UCB medicines can contact UCBCares / UCB Medical Information teams across the globe. Contact details can be found here.

Contact ucbCARES

Patients

Financial Assistance

Assistance

Newsroom

Newsroom

UCB’s Three-Point Plan to Help Combat COVID-19 in the U.S.


With the U.S. heavily impacted by the novel coronavirus, COVID-19, UCB is committed to playing our part to contribute our scientific expertise and resources to the greater response effort happening across the country and the world. This includes expanding our assistance programs to further help patients impacted by the pandemic.

Our actions are focused on three pillars - contributing to basic research and treatment development, offering our expertise globally to increase local testing capabilities, and supporting local communities through donations and direct support to patients and partners.

Examples of our actions in the U.S. include:

  • We are actively working with the Seattle Structural Genomics Center for Infectious Disease to identify crystal structures of SARS-CoV-2 proteins.
  • In addition to providing funding support to organizations in need during this challenging time, our research facility in Bedford, Massachusetts, donated safety glasses, gloves, disposable lab coats, protective suits and gowns, and bags of strip PCR tubes from our labs to be used by healthcare institutions and researchers in Massachusetts to test and treat patients with COVID-19.  
  • UCB is also supporting healthcare professionals in our company who wish to volunteer their expertise in line with local government needs and guidance.
  • Further, we have expanded our existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19. More details are below. 
  • UCB is a member of the COVID Research and Development Alliance

Frequently Asked Questions

As we navigate this unpredictable situation together as a global community, UCB’s commitment to supporting patients living with severe, chronic diseases remains unchanged. From our team at UCB, our hearts go out to all those affected by COVID-19, and we are here to help.

How has UCB's supply been impacted?

We are committed to assuring reliable supply of medicines in every market where we have a commercial presence. Despite the rapid emergence of the novel coronavirus and the challenge presented to healthcare systems around the globe, UCB has not experienced shortages for any of our products due to this epidemic.

Read More

Since the onset of the coronavirus outbreak, UCB has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. UCB leverages strategic buffer stock along with multi-sourcing for key materials in our global supply chain to mitigate the impact of supply disruptions due to events such as the current coronavirus outbreak.

Our global manufacturing and distribution network continues to be fully operational and UCB remains in constant contact with our global network of key suppliers, manufacturing partners, and distributors to identify potential risks and take appropriate measures to avoid any disruption. At this time, we do not anticipate any supply disruption of our products. As this global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicines.

Close

I am a patient, caregiver, or health care provider. Where do I go for support?

ucbCARES stands ready to help anyone impacted by COVID-19 find answers to their questions and ensuring they receive the respect and care they deserve during this concerning time.

Read More

Contact ucbCARES at +1-844-599-CARE (2273), via email at UCBCares@ucb.com, or visit: Patients

Close

What is UCB's approach to clinical trials during this time?

In March 2020, the evolving COVID-19 pandemic led UCB to halt recruitment into ongoing clinical studies and delay all new study starts. This decision was taken in the interest of public health safety and to help reduce the strain on healthcare systems across the world during a time of extraordinary medical emergency. As of mid-May 2020, UCB began to restart clinical study recruitment, including new study starts, at clinical trials sites that meet our restart criteria.

Read More

UCB continues to proactively monitor the COVID-19 situation and will take any necessary precautionary steps in the interest of public health. Healthcare professionals and patients with questions related to UCB medicines can contact UCBCares / UCB Medical Information teams across the globe. Contact details can be found here.

Close

I am facing hardship due to the COVID-19 pandemic and experiencing difficulty affording UCB medicines due to job loss, job furlough, or loss of insurance coverage. Where can I go for help?

We have expanded our existing Patient Assistance Program (PAP) to help eligible patients who have been impacted by COVID-19 by expediting enrollment to help ensure uninterrupted access to their medicines at no cost.

Read More

This change will help patients experiencing difficulty affording UCB medicines due to job loss, job furlough, or loss of insurance coverage during this unprecedented time. Contact ucbCARES at (844) 599-CARE (2273) or by email at UCBCares@ucb.com to see if you qualify for medicines at no cost.

Close

What action is UCB taking to protect its employees?

As local governments around the world announce increased measures to address the different stages of the COVID-19 crisis, UCB is continuously assessing the best precautionary health and safety measures for our colleagues and their families worldwide while remaining focused on insuring business critical activities for our patients.

Read More

We have instigated a travel freeze and have asked employees who are able to do so to work from home.  We are aware that not all employees can do their work remotely, therefore UCB is taking a high level of health and hygiene precautionary measures at all our site locations. These include increased and frequent cleaning and disinfection of sites, as well as continuing to implement social distance guidelines. We are also providing information to employees on how to stay as safe as possible at work and at home. We have a team in place who are continuously monitoring the situation.

Close

Has UCB experienced shortages for any of our products due to this epidemic, including for NAYZILAM® (midazolam) nasal spray CIV?

UCB has not experienced shortages for any of our products due to this epidemic, including for NAYZILAM® (midazolam) nasal spray CIV.

Read More

Midazolam Injection is currently on the FDA Drug Shortages list. The shortage is specific to the intravenously administered midazolam Injection. NAYZILAM is a nasal formulation of midazolam.
 
Full NAYZILAM Prescribing Information, including boxed warning regarding concomitant use of benzodiazepines and opioids.

Close